Shortage Watch Free FDA drug-shortage watch

← all medications

Gemfibrozil Tablet

Brand names: Lopid

Category: Endocrinology/Metabolism

Not specified 1

FDA status: To Be Discontinued · Last FDA update: Feb 10, 2026 · First posted: Feb 10, 2026 · 1 manufacturers, 1 listed presentations

As of Feb 10, 2026, the FDA lists Gemfibrozil Tablet as being discontinued. Of 1 manufacturer presentations, 1 Not specified.

Ask your pharmacist: which of the 1 manufacturers below can they order right now, and whether a different strength or form of Gemfibrozil Tablet is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.
Presentation & package NDCManufacturerAvailabilityFDA note
Lopid, Tablet, 600 mg (NDC 0071-0737-20)
NDC 0071-0737-20		 Pfizer Inc. Not specified Discontinuation of the manufacture of the drug.

Related medications in shortage

Other Endocrinology/Metabolism medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.

Change log

No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.

Cite this: “FDA drug-shortage status for Gemfibrozil Tablet (FDA data as of Feb 10, 2026). Shortage Watch, openFDA.”

Get an email when this record changes

One email, only when the FDA changes something for Gemfibrozil Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.

Check your inbox - click the confirmation link to activate alerts for Gemfibrozil Tablet.

Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.

Embed a live status badge: /badge/gemfibrozil-tablet.svg

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).